Chronic Myelogenous Leukemia (CML) Treatments
Find Chronic Myelogenous Leukemia (CML) Treatments
Dasatinib
What is Phyrago (Dasatinib)?
Related Clinical Trials
Summary: This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells an...
Summary: This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV reservoir. It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed viral load while on antiretroviral therapy (ART). Adults 18 years or older who have been on ART for at least 48 months and have had a suppressed HIV-1 viral load for at leas...
Summary: The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
Related Latest Advances
Brand Information
- newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
- chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
- Ph+ CML in chronic phase.
- newly diagnosed Ph+ ALL in combination with chemotherapy.
- Myelosuppression
- Bleeding-related events
- Fluid retention
- Cardiovascular toxicity
- Pulmonary arterial hypertension
- QT prolongation
- Severe dermatologic reactions
- Tumor lysis syndrome
- Effects on growth and development in pediatric patients
- Hepatotoxicity
b Includes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular.
c Adverse reaction of special interest with <10% frequency.
d Includes conjunctival hemorrhage, ear hemorrhage, ecchymosis, epistaxis, eye hemorrhage, gingival bleeding, hematoma, hematuria, hemoptysis, intra-abdominal hematoma, petechiae, scleral hemorrhage, uterine hemorrhage, and vaginal hemorrhage
bIncludes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular

- Advise pregnant women of the potential risk to a fetus
- Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with PHYRAGO and for 30 days after the last dose. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking PHYRAGO
- Advise women not to breastfeed during treatment with PHYRAGO and for 2 weeks after the last dose
- Missed Dose
- Grapefruit Juice
Bora Pharmaceutical Services Inc.
Mississauga, Ontario, L5N 6L4,
Canada
Marketed by:
Cycle Pharmaceuticals Ltd
Cambridge, CB3 0FA
United Kingdom













